









Markets
/
Stocks
/
nasdaq-ixhl
/

Incannex Healthcare Inc

IXHL

0.288USD

+0.038+15.20%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

100.14MMarket Cap

LossP/E TTM



Incannex Healthcare Inc

0.288

+0.038+15.20%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Incannex Healthcare Inc

Currency: USD Updated: 2026-02-06

Key Insights

Incannex Healthcare Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered undervalued, ranking 125 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Incannex Healthcare Inc's Score

Industry at a Glance

Industry Ranking

125 / 159

Overall Ranking

461 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Incannex Healthcare Inc Highlights

StrengthsRisks

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.

Growing

The company is in a growing phase, with the latest annual income totaling USD 86.00K.

Overvalued

The company’s latest PE is -0.27, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 3.67M shares, increasing 34.11% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 5.19.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Incannex Healthcare Inc is 5.67, ranking 153 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 18.21%.

Score

Industry at a Glance

Previous score

5.67

Change



Financials

5.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.76

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.51

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.98

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.09

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Incannex Healthcare Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Incannex Healthcare Inc is 8.94, ranking 2 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -0.27, which is -74.11% below the recent high of -0.07 and -863.56% above the recent low of -2.58.

Score

Industry at a Glance

Previous score

8.94

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 125/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for Incannex Healthcare Inc. The Pharmaceuticals industry's average is 7.85.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Incannex Healthcare Inc is 4.38, ranking 148 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 0.39 and the support level at 0.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.14

Change

0.24

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.012

Sell

RSI(14)

36.758

Neutral

STOCH(KDJ)(9,3,3)

25.774

Buy

ATR(14)

0.027

High Vlolatility

CCI(14)

-85.556

Neutral

Williams %R

68.929

Sell

TRIX(12,20)

-1.229

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

0.280

Buy

MA10

0.298

Sell

MA20

0.336

Sell

MA50

0.375

Sell

MA100

0.394

Sell

MA200

0.395

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Incannex Healthcare Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 1.06%, representing a quarter-over-quarter increase of 14.71%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Latham (Joel)

24.19M

+1433.21%

Valentine (Troy Robert)

12.34M

+1090.45%

Swan (Joseph)

2.57M

+14257.55%

Anastassov (George)

2.46M

+219.16%

Widdows (Peter)

1.96M

+622.84%

Arete Wealth Advisors, LLC

1.18M

Changoer (Lekhram)

639.55K

AdvisorShares Investments, LLC

471.28K

+37.02%

Virtu Americas LLC

402.44K

Jane Street Capital, L.L.C.

230.45K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Incannex Healthcare Inc is 3.11, ranking 108 out of 159 in the Pharmaceuticals industry. The company's beta value is 2.61. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.